High Tech Pharm Co Ltd
High Tech Pharm Co Ltd has a strong liquidity position, as evidenced by a current ratio of 5.67, indicating that the company has more than five times the current assets to cover its current liabilities. However, the company has a negative net cash position after subtracting total debt, which is a key liquidity flag. The company's price-to-book ratio is 1.32, and the price-to-tangible-book ratio is also 1.32, suggesting that the market values the company's equity at a moderate premium to its book value. In terms of profitability, High Tech Pharm Co Ltd has a return on equity (ROE) of 8.78% and a return on assets (ROA) of 7.99%, which are both positive indicators of the company's ability to generate returns from its equity and assets. The company's gross profit margin is 24.14% (calculated as gross profit of 16,944,464,260 KRW divided by revenue of 70,183,145,370 KRW), and its operating margin is 18.32% (calculated as operating income of 12,856,052,090 KRW divided by revenue of 70,183,145,370 KRW), both of which are strong indicators of the company's profitability. The company's revenue is primarily concentrated in its domestic and international markets, with no specific segment breakdown provided. The company's exposure to geographic markets is not detailed in the provided data, but the distribution of its products in both domestic and international markets suggests a diversified geographic presence. High Tech Pharm Co Ltd has a price-to-earnings (P/E) ratio of 15.01 and an enterprise value-to-revenue (EV/Revenue) ratio of 2.45, indicating that the company is valued at a moderate multiple relative to its earnings and revenue. The company's capital expenditure for the period was -1,926,449,790 KRW, suggesting a reduction in capital spending. The company's risk assessment indicates a medium liquidity risk and a low dilution risk. The key flag of negative net cash after subtracting total debt suggests potential liquidity constraints, but the company's strong operating cash flow of 17,028,160,110 KRW and free cash flow of 13,902,362,600 KRW provide a buffer against short-term liquidity pressures. Recent events and filings for High Tech Pharm Co Ltd are not detailed in the provided data, but the company's strong financial performance and liquidity position suggest a stable business environment. The company's financial health is supported by its strong operating cash flow and free cash flow, which are critical for maintaining operations and funding future growth.
Business. High Tech Pharm Co Ltd is a Korea-based company engaged in the manufacture of antibiotic pharmaceutical ingredients for injections, including sterile imipenem, sterile cilastatin sodium, and sterile meropenem, and distributes its products in both domestic and international markets.
Classification. High Tech Pharm Co Ltd is classified under the Healthcare economic sector, Pharmaceuticals & Medical Research business sector, and Pharmaceuticals industry, with a classification confidence of 0.92.
- High Tech Pharm Co Ltd has a strong liquidity position with a current ratio of 5.67.
- The company's return on equity (ROE) of 8.78% and return on assets (ROA) of 7.99% indicate strong profitability.
- The company's price-to-book ratio of 1.32 and price-to-tangible-book ratio of 1.32 suggest a moderate premium to book value.
- The company's operating cash flow of 17,028,160,110 KRW and free cash flow of 13,902,362,600 KRW provide a buffer against liquidity pressures.
- The company's capital expenditure for the period was -1,926,449,790 KRW, indicating a reduction in capital spending.
- # RATIONALES
- **margin_outlook_rationale**: The company's gross profit margin of 24.14% and operating margin of 18.32% suggest a stable margin outlook driven by strong profitability.
- **rd_outlook_rationale**: The company's R&D outlook is not detailed in the provided data, but its strong financial performance supports continued investment in research and development.
- Net cash is negative after subtracting total debt.